8-K: Cassava Sciences Expects to Release Phase 3 Trial Data for Alzheimer's Drug Simufilam by Year-End 2024

Cassava Sciences anticipates releasing top-line results from its 52-week Phase 3 RETHINK-ALZ trial of simufilam for Alzheimer's disease by the end of 2024, with $149 million in cash reserves to support operations into 2026.

Summary

• Cassava Sciences is a clinical-stage biotechnology company developing a new treatment for Alzheimer's disease.
• The company's leading drug candidate, simufilam, is currently in two Phase 3 clinical trials: RETHINK-ALZ and REFOCUS-ALZ.
• RETHINK-ALZ is a 52-week study, and REFOCUS-ALZ is a 76-week study.
• Both studies are fully enrolled, with approximately 1,900 patients in total.
• The company expects to release top-line data for RETHINK-ALZ by the end of 2024 and for REFOCUS-ALZ around mid-year 2025.
• Cassava Sciences reported a net loss of $27.9 million for Q3 2024.
• The company had $149 million in cash and cash equivalents as of September 30, 2024.
• The company has no debt.
• Cash and cash equivalents at year-end 2024 are estimated to be in a range from $117 to $127 million.
• An open-label extension study is ongoing for patients who completed the Phase 3 trials, with approximately 88% of eligible patients opting in.

Sentiment

Score: 6

Explanation: The sentiment is cautiously optimistic. While the company is making progress in its clinical trials and has a strong cash position, the significant net loss and the inherent uncertainties of drug development warrant a moderate sentiment score.

Positives

• The company has a strong cash position of $149.0 million, expected to fund operations into 2026.
• Both Phase 3 trials are fully enrolled, and the RETHINK-ALZ trial has reached its Last Patient/Last Visit (LPLV).
• The Data and Safety Monitoring Board (DSMB) has recommended the continuation of both Phase 3 trials without modification.
• A high percentage of patients (88%) are opting into the open-label extension study, indicating a positive outlook on the treatment.
• The company owns exclusive, worldwide rights to its investigational product candidates and related technologies, without royalty obligations to any third party.

Negatives

• The company reported a net loss of $27.9 million in Q3 2024.
• Research and development expenses were $17.7 million in Q3 2024.
• General and administrative expenses increased significantly to $12.9 million in Q3 2024, primarily due to higher legal-related expenses and increased compensation costs.
• The company intends to pay a previously announced $40 million SEC investigation settlement.

Risks

• Clinical trials may not be completed on the expected timelines.
• The drug candidate, simufilam, may not demonstrate safety or efficacy in treating Alzheimer's disease.
• The company may face challenges in obtaining regulatory approval for simufilam.
• Competitors may develop more effective treatments for Alzheimer's disease.
• The company's financial performance may be adversely affected by unexpected expenses or delays.
• The $40 million SEC investigation settlement could impact the company's financial position and reputation.

Future Outlook

The company expects to release top-line data for the RETHINK-ALZ trial by the end of 2024 and for the REFOCUS-ALZ trial around mid-year 2025. They project cash and cash equivalents to be between $117 and $127 million by year-end 2024, which is anticipated to support operations into 2026.

Management Comments

• We look forward to the release of top-line results from RETHINK-ALZ, our first Phase 3 trial for simulfilam, by the end of 2024.
• This will represent the culmination of three-plus years of concerted effort by our clinical team, principal investigators, patients and their caregivers.

Industry Context

This announcement is significant in the context of Alzheimer's disease drug development, a field with a high rate of clinical trial failures. The release of Phase 3 data for simufilam is highly anticipated, as a successful outcome could represent a major advancement in the treatment of this devastating disease.

Comparison to Industry Standards

• The drop-out rates of 21% for RETHINK-ALZ and 25% for REFOCUS-ALZ are generally consistent with industry expectations for Alzheimer's disease trials.
• For example, Biogen and Eisai's Phase 3 EMERGE and ENGAGE trials for aducanumab had dropout rates of around 30%.
• Eli Lilly's Phase 3 EXPEDITION3 trial for solanezumab had a dropout rate of approximately 25%.
• Roche's Phase 3 CREAD and CREAD2 trials for crenezumab had dropout rates of around 20%.
• The use of ADAS-Cog12 and ADCS-ADL as co-primary endpoints is standard practice in Alzheimer's disease clinical trials.
• These scales are widely accepted by regulatory agencies and have been used in numerous previous trials, including those for aducanumab, solanezumab, and crenezumab.

Legal Proceedings

• The company intends to pay a previously announced $40 million SEC investigation settlement, which has been placed in escrow.

Stakeholder Impact

• Shareholders: Potential impact depending on the results of the Phase 3 trials and the company's financial performance.
• Employees: The company's future and job security may be affected by the success or failure of simufilam.
• Patients: If approved, simufilam could offer a new treatment option for Alzheimer's disease.
• Suppliers: The company's relationships with suppliers may be impacted by the progress of the clinical trials and the company's financial position.
• Creditors: The company currently has no debt, so the direct impact on creditors is minimal.

Next Steps

• Report top-line data for the RETHINK-ALZ Phase 3 trial before the end of 2024.
• Report top-line data for the REFOCUS-ALZ Phase 3 trial around mid-year 2025.
• Continue the open-label extension study for up to 36 months or until a new drug application for simufilam has been reviewed by the FDA.
• Add cognition and plasma biomarker monitoring to the open-label extension trial.
• Pay the $40 million SEC investigation settlement.

Key Dates

Keywords

Alzheimer's disease, simufilam, Phase 3 clinical trials, RETHINK-ALZ, REFOCUS-ALZ, biotechnology, clinical-stage, drug development, neurodegenerative diseases, filamin A, amyloid-42, ADAS-Cog12, ADCS-ADL, cognitive impairment, dementia